Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- Tested for
- Solid Tumor
- Main trialPhase 1/2
- “The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.”In the company’s words, NCT07945821 on ClinicalTrials.gov
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Aug 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT07945821
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2028 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026